EGFR and non-small cell lung carcinoma: To test this possibility, we first used EGFR‐TKI (gefitinib) to inhibit both mutant and wild‐type EGFR downstream signals, and then analyzed ERCC1 protein and mRNA expression levels in both NSCLC cell lines and in NIH3T3 MEFs.